Amicus Therapeutics (NASDAQ:FOLD) Earns Overweight Rating from Analysts at Wells Fargo & Company
Wells Fargo & Company began coverage on shares of Amicus Therapeutics (NASDAQ:FOLD – Free Report) in a report issued on Thursday morning, MarketBeat reports. The brokerage issued an overweight rating and a $18.00 target price on the biopharmaceutical company’s stock. A number of other brokerages have also commented on FOLD. JPMorgan Chase & Co. decreased […]
More Stories
Judge Blocks White House’s Attempt to Defund Consumer Watchdog Agency
By Jack Phillips A federal judge ruled Tuesday that the White House cannot lapse its funding of the Consumer Financial...
Top 11 Hottest News Anchors in the World of All Time
News anchors have become a part of global personality. They are no longer just people who read headlines. Now, viewers...
OpenAI Looking to Hire ‘Head of Preparedness’ to Tackle AI Dangers
By Naveen Athrappully OpenAI is seeking to hire a candidate for the post of “Head of Preparedness” to tackle dangers...
Washington Offers 15-Year Security Guarantee to Ukraine as Part of Peace Plan, Zelenskyy Says
By Guy Birchall Washington has offered a 15-year security guarantee to Kyiv as part of a proposed peace plan, Ukrainian...
Kremlin Says Ukraine Tried to Attack Putin’s Residence, Peace Deal Stance Under Review
By Jack Phillips Ukrainian forces attempted to strike Russian President Vladimir Putin’s residence in the Russian city of Novgorod on...
BofA CEO Calls Economy ‘Pretty Solid’ but Warns Consumer Pullback Is Top Risk for 2026
By Tom Ozimek U.S. economic growth remains on solid footing heading into 2026, but the outlook hinges on whether American...